Despite its shortcomings, chemotherapy remains the first line of treatment against most cancers. But far too often it fails when a targeted tumor develops drug resistance. As resistance progresses, patients have fewer and fewer treatment options, and their cancer spreads. Over 90% of chemotherapy patient deaths are a result of the development of multidrug- resistance.
Verseon is developing novel chemotherapy agents whose efficacy is unimpaired by the development of resistance to other drugs. We are determined to prevent deaths from multidrug-resistant cancers.
Cancer patients requiring chemotherapy worldwide
Estimated size of global chemotherapy market